Profile data is unavailable for this security.
About the company
Seres Therapeutics, Inc. is a commercial-stage microbiome therapeutics company. It is focused on the development and commercialization of a novel class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. Its lead program, VOWST, is to prevent recurrence of Clostridioides difficile infection (CDI) in patients 18 or older following antibacterial treatment for recurrent CDI. Building upon VOWST, it is developing novel microbiome therapeutics, such as SER-155, to specifically target infections and antimicrobial resistance. SER-155, an oral microbiome therapeutic candidate consisting of a consortium of cultivated bacteria, is designed to prevent enteric-derived infections and resulting blood stream infections and induce immune tolerance responses to reduce the incidence of GvHD in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Revenue in USD (TTM)126.85m
- Net income in USD-82.68m
- Incorporated2010
- Employees233.00
- LocationSeres Therapeutics Inc101 Cambridge Park DriveCAMBRIDGE 02140United StatesUSA
- Phone+1 (617) 945-9626
- Fax+1 (302) 655-5049
- Websitehttps://www.serestherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PDS Biotechnology Corp | 0.00 | -43.89m | 130.58m | 25.00 | -- | 3.51 | -- | -- | -1.37 | -1.37 | 0.00 | 1.01 | 0.00 | -- | -- | 0.00 | -63.85 | -51.63 | -74.22 | -59.00 | -- | -- | -- | -- | -- | -27.82 | 0.3933 | -- | -- | -- | -5.11 | -- | -- | -- |
| Vigil Neuroscience Inc | 0.00 | -82.78m | 131.55m | 65.00 | -- | 1.27 | -- | -- | -2.12 | -2.12 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -52.16 | -- | -54.92 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
| Karyopharm Therapeutics Inc | 140.46m | -146.34m | 131.84m | 325.00 | -- | -- | -- | 0.9386 | -1.28 | -1.28 | 1.22 | -1.45 | 0.5298 | 1.67 | 4.24 | 432,187.70 | -55.19 | -53.02 | -72.56 | -65.85 | 96.08 | 97.18 | -104.18 | -125.15 | 2.99 | -9.66 | 2.25 | -- | -7.03 | 36.93 | 13.43 | -- | -- | -- |
| Citius Pharmaceuticals Inc | 0.00 | -37.35m | 131.89m | 22.00 | -- | 1.46 | -- | -- | -0.2367 | -0.2367 | 0.00 | 0.4989 | 0.00 | -- | -- | 0.00 | -37.14 | -30.26 | -39.48 | -32.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.1589 | -- | -- | -- |
| Adicet Bio Inc | 0.00 | -139.79m | 132.30m | 143.00 | -- | 0.5112 | -- | -- | -2.95 | -2.95 | 0.00 | 3.15 | 0.00 | -- | -- | 0.00 | -46.75 | -37.03 | -49.70 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
| aTyr Pharma Inc | 588.00k | -53.93m | 134.57m | 56.00 | -- | 1.58 | -- | 228.86 | -0.9029 | -0.9029 | 0.0099 | 1.24 | 0.0047 | -- | 0.2868 | 10,500.00 | -43.13 | -45.45 | -48.85 | -52.74 | -- | -- | -9,172.11 | -784.19 | -- | -- | 0.021 | -- | -96.60 | -- | -11.14 | -- | 47.98 | -- |
| Genelux Corp | 8.00k | -25.78m | 135.52m | 23.00 | -- | 8.84 | -- | 16,940.46 | -0.9811 | -0.9811 | 0.0003 | 0.5679 | 0.0004 | -- | -- | 347.83 | -131.24 | -- | -246.21 | -- | -- | -- | -322,287.50 | -- | -- | -- | 0.00 | -- | -98.46 | -- | -443.44 | -- | -- | -- |
| Corvus Pharmaceuticals Inc | 0.00 | -24.86m | 136.36m | 28.00 | -- | 3.20 | -- | -- | -0.5113 | -0.5113 | 0.00 | 0.6804 | 0.00 | -- | -- | 0.00 | -50.58 | -38.31 | -59.70 | -43.34 | -- | -- | -- | -- | -- | -12.88 | 0.00 | -- | -- | -- | 34.57 | -- | -37.45 | -- |
| Seres Therapeutics Inc | 126.85m | -82.68m | 137.83m | 233.00 | -- | -- | -- | 1.09 | -0.6062 | -0.6062 | 0.9495 | -0.3945 | 0.4149 | -- | -- | 544,407.80 | -27.04 | -41.51 | -36.82 | -54.13 | -- | -- | -65.18 | -170.14 | 1.25 | -9.21 | 2.41 | -- | 1,672.24 | 34.91 | 54.54 | -- | 32.72 | -- |
| Scpharmaceuticals Inc | 17.63m | -57.71m | 137.91m | 135.00 | -- | 5.61 | -- | 7.82 | -1.49 | -1.49 | 0.4545 | 0.6814 | 0.1713 | 0.7566 | 4.02 | 130,607.40 | -56.07 | -38.23 | -62.13 | -42.31 | 71.69 | -- | -327.29 | -1,360.16 | 5.44 | -16.60 | 0.6159 | -- | -- | -- | -48.79 | -- | -- | -- |
| Tevogen Bio Holdings Inc | 0.00 | -67.33k | 141.57m | 17.00 | -- | -- | -- | -- | -0.0004 | -0.0004 | 0.00 | -0.0045 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -8.19 | 1.74 | -- | -- | -- | 99.69 | -- | -- | -- |
| Renovaro Inc | 0.00 | -53.93m | 141.60m | 11.00 | -- | 0.8398 | -- | -- | -0.7661 | -0.7661 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -37.06 | -27.81 | -41.75 | -28.44 | -- | -- | -- | -- | -- | -24.38 | 0.0405 | -- | -- | -- | 65.02 | -- | -0.1538 | -- |
| I-Mab ADR | 3.82m | -202.51m | 142.35m | 220.00 | -- | 0.5983 | -- | 37.27 | -2.43 | -2.43 | 0.0459 | 2.94 | 0.0083 | -- | -- | 17,361.36 | -43.84 | -35.99 | -53.14 | -42.08 | 100.00 | -- | -5,302.03 | -496.71 | -- | -42.63 | 0.0171 | -- | 112.48 | -12.46 | 41.54 | -- | -4.66 | -- |
| Repare Therapeutics Inc | 97.86m | -45.69m | 144.31m | 179.00 | -- | 0.6168 | -- | 1.47 | -1.10 | -1.10 | 2.30 | 5.51 | 0.3265 | -- | 9.22 | 546,698.30 | -15.25 | -23.40 | -18.73 | -26.37 | -- | -- | -46.69 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
Data as of May 21 2024. Currency figures normalised to Seres Therapeutics Inc's reporting currency: US Dollar USD
33.88%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 22.65m | 15.00% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 6.58m | 4.36% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 6.26m | 4.15% |
| Hudson Bay Capital Management LPas of 31 Mar 2024 | 5.43m | 3.59% |
| Geode Capital Management LLCas of 31 Mar 2024 | 2.13m | 1.41% |
| Woodline Partners LPas of 31 Mar 2024 | 2.05m | 1.36% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.95m | 1.29% |
| BofA Securities, Inc.as of 31 Mar 2024 | 1.63m | 1.08% |
| Eversept Partners LPas of 31 Mar 2024 | 1.39m | 0.92% |
| Handelsbanken Fonder ABas of 31 Mar 2024 | 1.10m | 0.73% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
